CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy

The goal of this clinical trial is to learn if a commercially available cannabigerol (CBG)/cannabidiol (CBD) oil is safe, feasible to use, and can help reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in adults who have completed platinum-based chemotherapy for gastrointestinal cancers. The main questions it aims to answer are: Is CBG/CBD oil safe and well-tolerated over a 12-week treatment period? Can participants with CIPN use CBG/CBD oil consistently as part of their care? Does CBG/CBD oil help reduce pain, numbness, or other symptoms of CIPN? Participants will: Take CBG/CBD oil under the tongue (sublingually) twice daily for 12 weeks Complete regular symptom assessments and functional tests during study visits Provide blood samples for cannabinoid and metabolite level testing

NCT Number	NCT07016971
Lead Sponsor	Milton S. Hershey Medical Center
Conditions	Chemotherapy-Induced Peripheral Neuropathy
Enrollment	12 participants
Start Date	2026-04-03
Primary Completion	2029-04-03 (estimated)
Study Completion	2029-07-03 (estimated)
Updated on ClinicalTrials.gov	2026-05-11